Combination therapy increases the efficacy of docetaxel, vinblastine and tamoxifen in cancer cells

Journal of Cancer Research and Therapeutics

Volumn 10, Issue 3, 2014, Pages 715-721

  Samadi, Nasser ^a,b   Ghanbari, Parisa ^a,c   Mohseni, Mahsa ^a,c   Tabasinezhad, Maryam ^a,c   Sharifi, Simin ^c,d   Nazemieh, Hossein ^c,d   Rashidi, Mohammad Reza ^c,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemotherapy; docetaxel; H1299 cells; MDA MB 231 cells; vinblastine

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4',6 DIAMIDINO 2 PHENYLINDOLE; DOCETAXEL; TAMOXIFEN; VINBLASTINE; ANTINEOPLASTIC AGENT; TAXOID;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CANCER CELL LINE; MTT ASSAY; NON SMALL CELL LUNG CANCER; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; HUMANS; TAMOXIFEN; TAXOIDS; VINBLASTINE;

EID: 84920816898     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.139152     Document Type: Article

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10.
3. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008;1785:96-132.
4. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-91.
5. Herbst RS, Khuri FR. Mode of action of docetaxel-A basis for combination with novel anticancer agents. Cancer Treat Rev 2003;29:407-15.
6. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71.
7. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
8. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2:1-17.
9. Bogush T, Dudko E, Bogush E, Polotsky B, Tjulandin S, Davydov M. Tamoxifen non-estrogen receptor mediated molecular targets. Oncol Rev 2012;6:e15.
10. Martinez-Lacaci I, Garcia Morales P, Soto JL, Saceda M. Tumour cells resistance in cancer therapy. Clin Transl Oncol 2007;9:13-20.
11. Skidan I, Miao B, Thekkedath RV, Dholakia P, Degterev A, Torchilin V. In vitro cytotoxicity of novel pro-Apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL. Drug Deliv 2009;16:45-51.
12. Frei E 3rd, Karon M, Levin RH, Freireich EJ, Taylor RJ, Hananian J, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 1965;26:642-56.
13. Zoli W, Ricotti L, Dal Susino M, Barzanti F, Frassineti GL, Folli S, et al. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer 1999;81:609-15.
14. Crown J, Dieras V, Kaufmann M, von Minckwitz G, Kaye S, Leonard R, et al. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol 2002;3:719-27.
15. Samadi N, Bekele R, Capatos D, Venkatraman G, Sariahmetoglu M, Brindley DN. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie 2011;93:61-70.
16. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006;94:1604-9.
17. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9.
18. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-49.
19. Samadi N, Gaetano C, Goping IS, Brindley DN. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 2009;28:1028-39.
20. Riccardi A, Servidei T, Tornesello A, Puggioni P, Mastrangelo S, Rumi C, et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer 1995;31A: 494-9.
21. Rosetti M, Zoli W, Tesei A, Ulivi P, Fabbri F, Vannini I, et al. Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics. J Cell Physiol 2007;212:710-6.
22. Shurin GV, Tourkova IL, Kaneno R, Shurin MR. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 2009;183:137-44.
23. Kim YJ, Lee CJ, Lee U, Yoo YM. Tamoxifen-induced cell death and expression of neurotrophic factors in cultured C6 glioma cells. J Neurooncol 2005;71:121-5.
24. Tester W, Ackler J, Tijani L, Leighton J. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. Cancer J 2006;12:299-304.
25. Airoldi M, Cattel L, Pedani F, Marchionatti S, Tagini V, Bumma C, et al. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer. Acta Oncol 2003;42:186-94.
26. Airoldi M, Cortesina G, Giordano C, Pedani F, Bumma C, Gabriele P. Docetaxel and vinorelbine: An effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol 2003;20:19-24.
27. Bonneterre J, Campone M, Koralewski P, Blasinska-Morawiec M, Deporte-Fety R, Chatelut E, et al. Vinorelbine/docetaxel combination treatment of metastatic breast cancer: A phase I study. Cancer Chemother Pharmacol 2007;60:365-73.
28. Campone M, Blasinska-Morawiec M, Tekiela A, Koralewski P, Pouget JC, Douville I, et al. Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol 2009;63:937-43.
29. Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naive non-small-cell lung cancer in Taiwan. Lung Cancer 2007;56:363-9.
30. Esteban E, Modollel A, Gonzalez de Sande L, Palacio I, Muniz I, Fernandez Y, et al. Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: A dose-finding study. Breast Cancer Res Treat 2003;80:257-65.
31. Goodin S, Rao KV, Kane M, Dave N, Capanna T, Doyle-Lindrud S, et al. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2005;56:199-204.
32. Kornek GV, Ulrich-Pur H, Penz M, Haider K, Kwasny W, Depisch D, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001;19:621-7.
33. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999;26:3-7.
34. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: From genomics to mechanism. Oncogene 2003;22:7468-85.